Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a method to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a $73m series A financing, and a deal with Roche which has a potential biodollar value north of $750m, C4 Therapeutics co-founder and executive chair Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.
This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016. Further panel discussions and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?